ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,172.15
0.63%
Dow Jones
38,225.66
0.85%
Gold vs US Dollar
2,308.495
0.21%
Brent Oil
83.845
0.26%
Bitcoin
59,559.74
0.74%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allakos Inc (ALLK)

  7. Allakos Inc (ALLK) News

Allakos (ALLK)

Allakos Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALLK
DateTimeSourceHeadlineSymbolCompany
14/03/202420:02GlobeNewswire Inc.Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALLKAllakos Inc
06/03/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
06/03/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
05/03/202421:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
04/03/202422:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
26/02/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
26/02/202412:02GlobeNewswire Inc.Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024NASDAQ:ALLKAllakos Inc
21/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
21/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
21/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
17/02/202400:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
14/02/202421:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
14/02/202413:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
12/02/202412:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
12/02/202412:02GlobeNewswire Inc.Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionNASDAQ:ALLKAllakos Inc
02/02/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
02/02/202417:31Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALLKAllakos Inc
26/01/202421:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALLKAllakos Inc
26/01/202414:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALLKAllakos Inc
16/01/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLKAllakos Inc
16/01/202412:02GlobeNewswire Inc.Allakos Announces a Restructuring to Focus on Development of AK006NASDAQ:ALLKAllakos Inc
16/01/202412:00GlobeNewswire Inc.Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsNASDAQ:ALLKAllakos Inc
05/01/202421:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALLKAllakos Inc
05/12/202323:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
05/12/202323:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
05/12/202323:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLKAllakos Inc
04/12/202320:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
04/12/202320:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
04/12/202320:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLKAllakos Inc
27/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALLKAllakos Inc
 Showing the most relevant articles for your search:NASDAQ:ALLK

Your Recent History

LSE
MIN
Minoan
LSE
BARC
Barclays
LSE
TSCO
Tesco
LSE
GKP
Gulf Keystone Petroleum
LSE
FEVR
Fevertree Drinks
LSE
PTAL
Petrotal
LSE
BOO
Boohoo
LSE
LLOY
Lloyds Banking
LSE
TERN
Tern
LSE
INSP
Inspirit Energy
LSE
ASC
Asos
LSE
GENF
Genflow Biosciences
LSE
CNR
Condor Gold
LSE
GLEN
Glencore
LSE
ENET
Ethernity Networks
LSE
SOLG
Solgold
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved